Tempus AI (TEM) shares fell nearly 12% in recent Tuesday trading, a day after reporting an adjusted loss for Q3 on higher revenue and a deal to acquire Ambry Genetics for $600 million.
The company reported a Q3 adjusted net loss of $0.25 per diluted share. Tempus AI didn't provide adjusted figures for the year-ago period.
Analysts polled by Capital IQ expected an adjusted loss of $0.31.
Revenue for the quarter ended Sept. 30 was $180.9 million, up from $136.1 million a year earlier.
Analysts surveyed by Capital IQ expected $179.6 million.
The company said it continues to expect 2024 revenue of about $700 million. Analysts polled by Capital IQ expect $698.1 million.
Additionally, Tempus said it has agreed to acquire Ambry Genetics for $600 million in cash and shares to expand its cancer testing and genetic screening.
As part of the deal, $375 million will be paid in cash and $225 million in shares at closing, Tempus said. The deal is financed partly by $300 million in debt from lender Ares, it added.
Price: 43.75, Change: -5.76, Percent Change: -11.63
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。